Ascendis Pharma A/S
ASND
Clasificación en acciones
#1496
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing... Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
Precio por acción
$233.96
Capitalización bursátil
$14.59B
Cambio (1 día)
1.74%
Cambio (1 año)
14.01%
País
DK
Comercio Ascendis Pharma A/S (ASND)
Categoría
Healthcare
Ratio P/B de Ascendis Pharma A/S (ASND)
Ratio P/B al October 2026 TTM: 9.08
Según los informes financieros más recientes y el precio de las acciones de Ascendis Pharma A/S, el ratio P/B actual (TTM) es 9.08. Al final de 2023, el ratio P/B era -44.02.
Historial del ratio P/B de Ascendis Pharma A/S desde 2011 hasta 2026
Ratio P/B al final de cada año
| Año | Ratio P/B | Cambiar |
|---|---|---|
| 2026 (TTM) | 9.08 | -112.46% |
| 2024 | -72.81 | 65.40% |
| 2023 | -44.02 | -281.27% |
| 2022 | 24.28 | 231.17% |
| 2021 | 7.33 | -10.96% |
| 2020 | 8.24 | -14.77% |
| 2019 | 9.66 | 20.55% |
| 2018 | 8.01 | 34.59% |
| 2017 | 5.95 | 105.99% |
| 2016 | 2.89 | -12.94% |
| 2015 | 3.32 | -42.28% |
| 2014 | 5.75 | -75.49% |
| 2013 | 23.47 | -76.31% |
| 2012 | 99.06 | 0.00% |
| 2011 | 0.00 | 0.00% |
Ratio P/B de empresas similares o competidoras
| Empresa | Ratio P/B | Diferencia del ratio P/B | País |
|---|---|---|---|
| 6.251 | -31.12% |
US
|
|
| 13.2547 | 46.05% |
US
|
|
| 4.208 | -53.63% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -31.88% |
NL
|
